Navigation Links
Anti cancer virotherapy well tolerated in first human administration, research finds

An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.

The research was presented to the third International Meeting on Replicating Oncolytic Virus Therapeutics, on Friday 11 March by Newcastle University associate professor, Darren Shafren.

The technology is licensed to Australian Stock Exchange listed biotechnology company, Psiron Limited (ASX:PSX).

Professor Shafren has previously tested this virotherapy on cancer tumours in mice and this is the first testing in humans. Two patients only were approved to receive this virotherapy.

Professor Shafren reported to the conference that this research team had injected a single dose of Coxsackie A21 (CVA21) virus directly into the advanced melanoma tumours of these patients with end stage disease.

Both patients had many sites of spread melanoma tumours and injected and non-injected tumours were subsequently removed from the patients.

Professor Shafren's group observed no "systemic toxic effects or localised inflammation" as a result of the injections of the viral material and basic blood chemistry and liver enzyme levels remain unchanged in the these two patients.

Professor Shafren told conference delegates that these findings suggested that administration of a single dose of CVA21 directly into a cancerous tumour was well tolerated.

"Administration of CVA21 may be of potential therapeutic benefit in controlling the spread of melanoma," Professor Shafren said.

CVA21 is one of a small group of naturally occurring rather than genetically modified viruses the Shafren team has been investigating as potential therapies for different hard to treat malignancies including melanoma and ovarian cancer.

These viruses occur naturally and routinely in the community causing mild infections in adult humans.
'"/>

Source:SciWords


Page: 1 2

Related biology news :

1. Viral DNA sequence a possible trigger for breast cancer
2. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
3. Its not all genetic: Common epigenetic problem doubles cancer risk in mice
4. Columbia research lifts major hurdle to gene therapy for cancer
5. Combination therapy boosts effectiveness of telomere-directed cancer cell death
6. Mitochondrial DNA mutations play significant role in prostate cancer
7. New imaging method gives early indication if brain cancer therapy is effective, U-M study shows
8. BRCA1 causes ovarian cancer through indirect, biochemical route
9. Researchers identify target for cancer drugs
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. First atlas of key brain genes could speed research on cancer, neurological diseases
Post Your Comments:
(Date:5/23/2013)... per year, carrying more than 284 million tons of cargo, ... dollars in toll fees for the Panama Canal Authority. Each ... of water are used from Gatun Lake, which is also ... in the isthmus. , However, the advent of very ... the ships at sea, has demanded change. The Panama Canal ...
(Date:5/23/2013)... Some prostate cancer patients unnecessarily undergo surgery or ... differences between slow-growing and aggressive forms of the ... Johns Hopkins Medical Institutes are developing technology that ... opt for relatively mild treatments or take drastic ... Anant Madabhushi, an associate professor of biomedical engineering ...
(Date:5/23/2013)... , the team reveal the interplay of brain chemicals ... the Wellcome Trust and BBSRC. , By changing ... our perceptual abilities. While these changes can affect the ... the fidelity of that response. , Lead ... you communicate with others, you can make yourself better ...
Breaking Biology News(10 mins):Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3
... Bacillus anthracis, the causative agent of anthrax, has been ... Drug Administration (FDA). The test, known as the Gamma ... Army Medical Research Institute of Infectious Diseases (USAMRIID) to ... specimens. The original form of the Gamma Phage Assay ...
... Scientists at The Scripps Research Institute have solved the ... TLR3, an acronym for Toll-like receptor three. In an ... described as a large horseshoe-shaped coil composed of 23 ... TLR3 that have never been seen before, an essential ...
... anthracis, the causative agent of anthrax, has been cleared ... Administration (FDA). The test, known as the Gamma Phage ... Medical Research Institute of Infectious Diseases (USAMRIID) to improve ... The original form of the Gamma Phage Assay was ...
Cached Biology News:'Mad cow' proteins successfully detected in blood 2'Mad cow' proteins successfully detected in blood 3Scripps research scientists solve structure of a critical innate immune system protein 2Scripps research scientists solve structure of a critical innate immune system protein 3Scripps research scientists solve structure of a critical innate immune system protein 4Anthrax test, developed by army and CDC, receives FDA approval 2Anthrax test, developed by army and CDC, receives FDA approval 3
(Date:5/24/2013)... May 24, 2013 Dr. Ingrid Warmuth and ... Swedesboro, NJ, are proud to announce an Open House at ... place on Saturday, June 8th from 10 AM to 2 ... Newport, MHS, PA-C and staff will be on hand to ... and aesthetic treatments, and provide complimentary cosmetic consultations. There will ...
(Date:5/24/2013)... , May 24, 2013 Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... Linemeyer , Ph.D., the Company,s Vice President, Biology ... Investor Relations & Corporate Communications, will present an overview ... at 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... CASTLE ROCK, Colo. , May 23, 2013 /PRNewswire/ ... vitro diagnostic company focused on obtaining FDA clearance ... APPY1 , today announced the pricing of an underwritten ... and related warrants to purchase 3,500,000 shares of its ... share at a combined public offering price of $1.25 ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... , TAI,AN CITY, China, ... Bulletin Board: CBPO) ("China Biologic" or the "Company"),one ... People,s,Republic of China ("PRC"), today announced that on ... contemplated by the security,purchase agreement initiated on June ...
... , BOSTON, June 11 Allied Minds has established ... from tinnitus (ringing in the ear). Allied Minds, a ... ventures, will provide the initial funding and has partnered ... to establish SoundCure, LLC to commercialize a novel acoustic ...
... Surgical Company (Nasdaq: STAA ), a leading ... today announced that the FDA has granted 510(k) clearance ... Affinity(TM) Collamer(R) Three-Piece NTIOL and the Elastimide(TM) Silicone NTIOL. ... new era of insertion devices for the company and ...
Cached Biology Technology:China Biologic Products Closes the $9.6 Million Private Placement 2China Biologic Products Closes the $9.6 Million Private Placement 3China Biologic Products Closes the $9.6 Million Private Placement 4Allied Minds Establishes New Company to Commercialize Novel UC Irvine Tinnitus Therapy 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 2STAAR Surgical Receives FDA Clearance for the Epiphany(TM) Injector System 3
...
...
... used in conjuction with Annexin V-FITC to ... stages of apoptosis (Annexin V positive, PI ... stages of apoptosis or already dead (Annexin ... in the orange range of the spectrum ...
BD Biocoat Matrigel Matrix Thin Layer 35 mm Culture Dishes...
Biology Products: